Rainbow Genomics is a pioneer in the commercialization of next-generation sequencing-based, diagnostic and preventive health care solutions to individuals in Asia.
We are committed to providing clinically-validated and evidence-based genetic tests to patients in Asia. We specialize in providing whole-exome-sequencing, pharmacogenomic, cancer, heart health, skin and nutritional health tests, enabling individuals and their physicians to use genomic information for diagnosis, treatment and disease prevention.
Coupled with our industry-first "Double Interpretation", provided simultaneously by U.S. and Japanese medical Institutions, we target unique Asian genetics to improve overall diagnostic yield.
Rainbow is both a new product developer and a distributor of U.S.-based genetic assessment applications.
Our market coverage includes pediatric and adult hereditary disorders, pharmacogenomics, and common disease/genetic risk assessment with clinical utilities. We understand how to integrate U.S. clinical best practices with localized "product components" to address various market segments.
We co-developed U.S.-based clinical applications with our institutional partners, and deploy credible clinical assessment products through highly-effective channels, to address both the domestic and medical tourism markets in Hong Kong, Japan and other Asian countries
Our management and clinical advisory teams consist of genetics, health care, ethics and public policy experts with substantial research and clinical experience. We deliver clinical applications via multiple clinical platforms provided by the following medical institutions and companies -
Baylor Genetics (Baylor)
Consultagene from Baylor College of Medicine
OneOme (established by Invenshure and Mayo Clinic)
Juntendo University Medical School, Center for Intractable Disease Research, Japan
Macrogen Clinical Lab, USA
Macrogen, South Korea
Multiple CAP (College of American Pathologists)-accredited and CLIA (Clinical Laboratory Improvement Amendments)-certified DNA sequencing laboratories
Our Primary Product Line - Clinical Whole Exome Sequencing tests
The human genome consists of 3 billion nucleotides or “letters” of DNA. Only a small fraction, about 1.5% of the genome, contains genes that encode proteins, which control various functions in the body. Much of what we know about genetic disorders are based on these genes, or what we collectively called the exome. An exome contains more than 22,000 genes.
The Rainbow whole exome sequencing tests analyze over 22,000 genes, and provide clinical reports that are based on clear medical evidence.
Most direct-to-consumer tests provide hundreds or even thousands of genetic findings that lack clinical utilities. Unlike these "recreational genetic tests", the Rainbow whole exome sequencing tests provide clinically- actionable results related to disorders for which your physicians can manage, treat or prevent.
Unlike many genetic tests using a small number of genes (1-200 genes in a fixed panel), Rainbow utilizes the entire exome for analysis and clinical interpretation. Analyzing the entire exome reduces the risk of not including sufficient Asian specific genes. This is a concern because many of these gene panels were designed based on clinical studies using Caucasian patients in the U.S. and Europe. There is often insufficient evidence to confirm the clinical utilities of these genes for Asian patients. Whole exome sequencing test reduces this risk.
As new genetic variants are discovered, especially by Asian clinicians, and more variants of uncertain clinical significance (VUS) are reclassified as pathogenic or likely-pathogenic mutations, we can provide timely reports for previously-unresolved clinical cases. This is feasible because we sequence over 22,000 genes for each patient.
Our clinical interpretation follows the current ACMG (American College of Medical Genetics and Genomics) guidelines. The clinical partners also issue physician reports signed-off by their board-certified medical directors or clinical geneticists.
Clinical exome sequencing performed at CAP (College of American Pathologists) accredited and/or CLIA (Clinical Laboratory Improvement Amendments) certified laboratories.
Patient data privacy – Rainbow follows the U.S. Health Insurance Portability and Accountability Act (HIPAA) privacy rules, established to protect the confidentiality of patients' individually identifiable health information.
Japanese Clinical Guidelines
Additional clinical interpretation provided by the Juntendo University Medical School is in compliance with Japan’s clinical testing guidelines
Rainbow Genomics maintains operations in the U.S. and Hong Kong.
Our English-speaking, Hong Kong-based project managers work closely with ordering physicians all over Asia to collect patient samples, manage testing process, and coordinate physician report delivery.
Our partner laboratories, U.S. and Japanese medical institutions support the entire clinical testing process.
Our partner genetic counselors and physicians based in Hong Kong, Shenzhen (China), and the U.S. provide bilingual (English with Japanese, Mandarin or Cantonese) genetic counseling to our patients, and consultation to physicians in local communities.